Business
Atea Pharmaceuticals Announces Upcoming Investor Events
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced
About this update from Atea Pharmaceuticals, Inc.
[{"type":"text","content":"BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Atea management will participate in the following investor events in September. Bemnifosbuvir Global Phase 3 Registrational Trial in Non-Hospitalized Patients: Company management will host a conference call on Tuesday, September 13, 2022 at 8:30 a.m. ET to provide details on the study design of the global Phase 3 registrational trial of bemnifosbuvir and program strategy for the treatment of COVID-19. The event can be accessed here. Morgan Stanley 20th Annual Global Healthcare Conference: Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with members of the Atea management team, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 12:55 p.m. ET. The event can be accessed here. Live webcasts and recordings of these presentations will be available on the Company’s website at https://ir.ateapharma.com/news-and-events/events-and-presentations. About Atea Pharmaceuticals Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with severe viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Currently, Atea is focused on the development of orally-available antiviral agents for difficult-to-treat, severe viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus (HCV), dengue virus and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com. Forward-Looking Statements This press release contains forward-looking statement...